SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 6 of 85
Word Count: 1498
Character Count: 9403

Document Content:

in full). Over-allotment Option We have granted the underwriters a 30-day option to purchase up to an additional shares of our common stock at the initial public offering price, less underwriting discounts and commissions, solely to cover over-allotments, if any. Use of Proceeds We estimate that the net proceeds to us from this offering, after deducting the underwriting discounts and estimated offering expenses payable by us, will be approximately $ million, or approximately $ million if the underwriters exercise their over-allotment option in full, based on the assumed initial public offering price of $ per share. The net proceeds received by us from this offering will be used primarily to fund the RELIVE clinical trial and the associated manufacturing activities required to support such trial. The remaining portion of the net proceeds will be used to fund working capital and general and administrative expenses. See “ Use of Proceeds .”

Underwriters’
Warrants The
registration statement of which this prospectus is a part also registers the offer and sale of common stock purchase warrants
to be issued to the underwriters (the “Underwriters’ Warrant”) to purchase shares of our common stock
(or 5% of the shares of common stock sold in this offering), including any shares of common stock sold pursuant to the exercise of
the underwriters’ over-allotment option, and the shares of our common stock issuable upon exercise of the Underwriters’
Warrants. The Underwriters’ Warrants are being issued to the underwriters as a portion of the underwriting compensation
payable in connection with this offering. The Underwriters’ Warrants are exercisable at any time, and from time to time,
in whole or in part, from the first day of the seventh month after the closing of this offering, to the date that is five years from
the date of commencement of sales in this offering, at an exercise price equal to the initial public offering price of the shares
of common stock. Please see “ Underwriting — Underwriters’ Warrants ” for further information.

Listing We
have applied to have our common stock listed on Nasdaq. No assurance can be given that our listing will be approved by
Nasdaq or that a trading market will develop for our common stock. We will not proceed with this offering in the event that our common
stock is not approved for listing on Nasdaq.

Proposed
Nasdaq symbol “BVXX”

Risk
Factors Investing
in our common stock is speculative and involves a high degree of risk . See “ Risk Factors ” beginning on
page 10 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide
to invest in our common stock.

Lock-Up In
connection with this offering, we, our executive officers, directors, and our existing stockholders have agreed not to offer, sell
or otherwise transfer or dispose of any shares of our capital stock for a period of six (6) months following the closing of this
offering. See “ Underwriting ” beginning on page 116 for more information.

Transfer
Agent The
transfer agent and registrar for our common stock is Issuer Direct Corporation.

(1)	The
number of shares of our common stock to be outstanding upon completion of this offering will be
shares assuming no exercise of the over-allotment by the underwriters, which is based on 5,712,645 shares of our common stock outstanding
as of December 31, 2025, and 7,664,988 shares of common stock being issued upon the closing of this offering in connection
with the conversion of: (i) 1,565,000 shares of our existing Series A Preferred Stock into 1,565,000 shares of common stock (assuming
an initial public offering price of at least $10.00 and an assumed conversion price of $10.00) and (ii) $11,333,146 of
our existing convertible notes into 6,099,988 shares of our common stock (assuming an initial public offering price of
at least $10.00 and an assumed conversion price of $10.00), and excludes, as of the date of this prospectus:

●	shares
of common stock issuable upon the exercise of the Underwriters’ Warrants;

●	950,500 shares of our common stock reserved for
issuance under stock option agreements issued pursuant to the BioVentrix 2024 Equity Incentive Plan (the “2024 Plan”);
and

shares of our common stock (which is equal to         % of our issued and outstanding common
stock immediately after the consummation of this offering) reserved for future issuance under the BioVentrix, Inc. 2026
Equity Incentive Plan (the “2026 Plan”), which will become effective as of the closing of this offering.

Unless
otherwise indicated, this prospectus reflects and assumes (i) no exercise by the underwriters of their over-allotment option and (ii)
no exercise of the outstanding stock options described above.

SUMMARY
OF CONSOLIDATED FINANCIAL INFORMATION

The following tables
set forth summary financial and other data for the periods ended and at the dates indicated below. Our summary financial information
for the years ended December 31, 2025 and 2024 and as of December 31, 2025 and 2024 has been derived from
our audited financial statements included in this prospectus. The financial data set forth below should be read in conjunction with “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and notes thereto included
elsewhere in this prospectus.

For
the Year Ended December
31, 2025 For
the Year Ended December

Statement of Operations Data:

Gross (loss) profit $	- $	-

Operating expense 6,270,430 3,562,516

Operating loss (6,270,430	) (3,562,516	)

Other expenses (income) 1,397,241 288,158

Net loss before taxes (7,667,671	) (3,850,674	)

Income tax expense (benefit) - -

Net loss (7,667,671	) (3,850,674	)

Net loss per share of common stock:

Basic $	(1.35	) $	(0.72	)

Weighted-average shares of common stock outstanding:

Basic 5,696,603 5,355,663

Balance
Sheet

As of December 31, 2025 As of December 31, 2024

Balance Sheet Data:

Cash $	1,838,121 $	2,637,635

Working capital (deficit) $	(11,592,497	) $	(4,989,308	)

Total assets $	2,568,861 $	3,279,249

Total liabilities $	15,134,042 $	8,318,384

Additional paid-in capital $	218,675,435 $	218,533,820

Accumulated deficit $	(231,241,344	) $	(223,573,673	)

Total stockholders’ deficiency $	(11,965,181	) $	(5,039,135	)

RISK
FACTORS

investment in our common stock is speculative and involves a high degree of risk. You should carefully consider the risks
described below, which we believe represent certain of the material risks to our business, together with the information contained elsewhere
in this prospectus, before you make a decision to invest in our shares of common stock. Please note that the risks highlighted here are
not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial or
unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown to
us actually occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading
price of our securities could decline and you could lose all or part of your investment.

Risks
Related to Our Industry and Business

have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we ever generate revenue or achieve
profitability (of which no assurances can be given), we may not be able to sustain it.

have incurred significant losses since our inception and expect to continue to incur losses for the foreseeable future. We have reported
net losses of approximately $3.9 million and $7.7 million for the years ended December 31, 2024 and 2025, respectively. As a
result of these losses, as of December 31, 2025, we had an accumulated deficit of approximately $231.2 million. To date,
we have financed our operations primarily through debt and equity financings. We expect to continue to incur significant research and
development, regulatory, sales and marketing and other expenses as we expand our marketing efforts to increase adoption of our product
candidates, expand existing relationships with our customers, obtain regulatory clearances or approvals for our planned or future product
candidates, conduct clinical trials on our existing and planned or future product candidates and develop new product candidates or add
new features to our existing product candidates. In addition, we expect our general and administrative expenses to increase following
this offering due to the additional costs associated with being a public company. The net losses that we incur may fluctuate significantly
from period to period. We will need to generate significant revenue in order to achieve and sustain profitability. Even if we ever generate
revenue or achieve profitability (of which no assurances can be given), we cannot be sure that such revenues will continue or that we
will remain profitable for any substantial period of time.

will require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or
at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce
or eliminate our product development programs, commercialization efforts or other operations.